Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.
- DOI
- 10.1158/1078-0432.ccr-26-1456
- Published
- 2026 Jul 23
- Container
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/1078-0432.ccr-26-1456,
title = {Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.},
author = {Wainberg ZA and Lee KW and Kim JG and Devoe C and Strickler JH and Baum J and Jia C and Kagey MH and Sirard CA and Stein A and Scott AJ and Pelster M and Moehler M and Han SW},
year = {2026},
journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
doi = {10.1158/1078-0432.ccr-26-1456},
url = {https://doi.org/10.1158/1078-0432.ccr-26-1456}
}RIS
TY - JOUR TI - Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial. AU - Wainberg ZA AU - Lee KW AU - Kim JG AU - Devoe C AU - Strickler JH AU - Baum J AU - Jia C AU - Kagey MH AU - Sirard CA AU - Stein A AU - Scott AJ AU - Pelster M AU - Moehler M AU - Han SW PY - 2026 JO - Clinical cancer research : an official journal of the American Association for Cancer Research DO - 10.1158/1078-0432.ccr-26-1456 UR - https://doi.org/10.1158/1078-0432.ccr-26-1456 ER -
APA
ZA, W., KW, L., JG, K., C, D., JH, S., J, B., C, J., MH, K., CA, S., A, S., AJ, S., M, P., M, M., & SW, H. (2026). Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-1456
Source records
- pubmed · retrieved 2026-09-27T00:01:33.289Z